Stat Recursion’s Incoming CEO Najat Khan to Lead Company into Next Phase
LONDON — Over the past year, Najat Khan has played a key role at Recursion Pharmaceuticals, the AI-driven drug development company. Since joining, she has helped advance the company’s drug pipeline while also trimming projects that did not meet expectations. Additionally, Khan has been instrumental in guiding Recursion through its merger with Exscientia.
Originally hired as chief commercial officer and head of research and development, Khan is now set to become Recursion’s CEO in the new year. This leadership change comes as the company shifts its focus toward later-stage drug development programs, requiring a different set of skills at the helm.
Leadership Transition Reflects Shift in Company Strategy
Chris Gibson, one of Recursion’s founders and the current CEO, announced earlier this month that he will step down from his role. Gibson explained to STAT that the company’s evolving priorities call for a leader with expertise suited to advancing clinical-stage programs. He will remain involved as the board chair, ensuring continuity while Khan takes over daily operations.
This transition marks a significant moment for Recursion as it moves beyond early-stage research and development. The company aims to demonstrate tangible results in drug development, leveraging AI technology to bring new therapies closer to market.
Stat Recursion’s Incoming CEO Faces Challenge of Delivering Results
With Najat Khan stepping into the CEO position, expectations are high for her to build on the progress made so far. The focus will be on translating Recursion’s AI-driven discoveries into successful late-stage clinical programs. Khan’s experience in both commercial strategy and R&D positions her well to lead the company through this critical phase.
The industry has seen considerable hype around AI in drug development, but Recursion’s incoming CEO understands the importance of moving beyond promises. The company must now show clear, measurable outcomes to validate its approach. Khan’s leadership will be central to achieving these goals and driving Recursion’s future growth.
For more stories on this topic, visit our category page.
Source: original article.